<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02082353</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT RDCRN PIDTC-6903</org_study_id>
    <nct_id>NCT02082353</nct_id>
  </id_info>
  <brief_title>Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995</brief_title>
  <official_title>Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rare Diseases Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Primary Immune Deficiency Treatment Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic granulomatous disease (CGD) is an inherited immune system abnormality in which bone
      marrow transplantation (BMT) has been shown to be curative. However the risks of
      transplantation are high and not all patients with CGD may need to undergo this high risk
      procedure. This study will determine the long term medical condition and daily functioning of
      participants with CGD after a transplant and if possible, compare these results to
      participants who do not undergo a transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic granulomatous disease (CGD) is an immune deficiency where the neutrophils (a type of
      white blood cell that kills bacteria and fungi) do no work properly. Some individuals with
      CGD have neutrophils that do not work at all, whereas others have neutrophils that work
      partially, but not normally. In the past (over 20 years ago), most individuals with CGD were
      managed with antibiotics and antifungal medications alone. As the science of blood and marrow
      transplant (BMT) improved, some with CGD started to receive a BMT. It remained controversial
      whether individuals with CGD should receive a BMT or medical management alone (antibiotics,
      antifungals, and other treatments that do not include BMT).

      The aim of this natural history study is to better define the role of BMT compared to medical
      management of CGD. Specifically, what are the outcomes of BMT versus medical management
      alone, why do some individuals with CGD benefit from BMT, and what are the long-term outcomes
      of both approaches. Researchers are interested in how individuals with CGD who have no
      neutrophil function may differ from those with some neutrophil function, how the types of
      infections and inflammatory complications of CGD impact on survival and how BMT may improve
      these complications. There are also questions as to how the types of bacteria (called the
      microbiome) found in the gastrointestinal tract (colon, large intestine) of individuals with
      CGD influences certain inflammatory complications (such as colitis), and how BMT changes the
      microbiome in individuals with CGD. All of this will help doctors in the future to better
      treat patients with CGD.

      This study includes a retrospective (looking back into the past), cross-sectional (one time
      collection of information and/or research testing) and a prospective (looking from today and
      into the future) component. These are known as longitudinal studies (e.g., looking at
      information of participants over time).

      Persons with CGD who were born 1988 to the present day are eligible, regardless of whether
      they received a BMT (as long as the BMT was after 1995) or medical therapy only. Individuals
      who are newly diagnosed with CGD can also be enrolled and followed longitudinally (over
      time), to determine their outcome from the choice of therapy that is made. An important
      component of this study is the 'cross sectional' study, where participants with more than 3
      years of follow-up after transplant or diagnosis are asked to provide additional research
      blood work, and information is gathered regarding long-term transplant outcomes such as
      infections, graft-versus-host disease, autoimmune diseases, and quality of life. In addition,
      the participants will be asked to provide stool samples to allow investigators to look at how
      certain bacteria found in the gut (called the microbiome) affect complications of CGD, such
      as gastrointestinal disease. This will allow primary immune deficiency investigators/doctors
      to better understand the outcomes of different therapeutic approaches and to best design new
      treatments and clinical trials in the future for children with CGD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>HCT to date of death, up to an expected average of 3 years</time_frame>
    <description>The event analyzed is death from any cause. The time from HCT to death or last follow up will be analyzed. Cause of death will also be collected. Surviving patients will be censored at the time of last observation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>an expected average of 3 years</time_frame>
    <description>Engraftment will be measures in whole blood using either fluorescent in situ hybridization (FISH) for sex chromosomes or short tandem repeat polymerase chain reaction (PCR) or (STRs) in whole blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Measures</measure>
    <time_frame>an expected average of 3 years</time_frame>
    <description>Age appropriate testing will be performed at the cross-sectional visit in patients surviving at least two years posttransplant:
Pediatrics quality of life (QL) Family Impact Module, Parent Report
Peds QL Infant Scales Module (ages 1-24 months), Parent Report
Peds QL Generic Core Scales for Toddlers (ages 2-4 yr), Parent Report
Peds QL Generic Core Scales (ages 5-25 yr), Child/Parent Reports
Peds QL Transplant Module
Standard Form (SF)-36 (adult)
Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT BMT) (adult)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections</measure>
    <time_frame>an expected average of 3 years</time_frame>
    <description>CGD or transplant-related and transplant-related infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autoimmune or inflammatory complications</measure>
    <time_frame>an expected average of 3 years</time_frame>
    <description>- For HCT subjects, inflammation (inflammatory complications) includes chronic graft-versus-host disease (GVHD)</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">1480</enrollment>
  <condition>Granulomatous Disease, Chronic</condition>
  <arm_group>
    <arm_group_label>Retrospective CGD Cohort</arm_group_label>
    <description>Longitudinal analysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective CGD Cohort</arm_group_label>
    <description>Longitudinal analysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCT CGD Cohort</arm_group_label>
    <description>Cross-sectional analysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Non-Transplant CGD Cohort</arm_group_label>
    <description>Longitudinal analysis</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood, skin swabs and stool samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Institutions participating in Rare Diseases Clinical Research Network (RDCRN)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant Inclusion Criteria (Part 1 - Longitudinal Analysis)

               -  CGD Patients Undergoing Transplant 1995 to Present with Birth Year In or After
                  1988

                    1. CGD Patients will be Defined by both Defective Neutrophil NADPH Oxidase
                       Function and by Clinical History Consistent with CGD

                       Patients must have both of:

                       A functional assay demonstrating abnormal NADPH oxidase function (see A
                       below); AND Clinical history consistent with CGD (see B below).

                       *************************************************************************

                       Patients must have both &quot;A&quot; and &quot;B&quot;:

                       A. Function: Assays of NADPH Oxidase Function

                       I. Dihydrorhodamine (DHR) Assay:

                         -  Blood sample was obtained at a time when patient was clinically stable
                            and not critically ill, with control samples performed simultaneously
                            indicating a qualified assay; and

                         -  Assay unequivocally demonstrates CGD with an stimulation index (SI) SI
                            &lt; 35 or equivalent. Assay report, including mean fluorescence intensity
                            (MFI) from unstimulated and stimulated samples and gating strategy,
                            must be de-identified and provided. OR

                       II. Nitroblue Tetrazolium Oxidation Test (NBT):

                       o Diagnostic of CGD (reported as reduced granulocyte oxidative response).
                       Report must be de-identified and provided. AND

                       B. Clinical History: One or More of the Following:

                         -  Severe and/or recurrent infection (liver, perirectal or lung abscess;
                            pneumonia; adenitis; or osteomyelitis) due to, for example,
                            Staphylococcus aureus, Burkholderia sp, Serratia marcescens,
                            non-albicans Candida sp, Aspergillus sp or other mold; or Nocardia sp
                            or other deep tissue infection characteristic of CGD

                         -  Sterile granulomatous disease in respiratory, gastrointestinal or
                            urogenital tracts; or Crohn's disease-like colitis

                         -  A family history consistent with either X-linked or autosomal recessive
                            CGD

                       In cases where either functional assay (A) or history (B) is equivocal, one
                       or more of the following may be used to confirm a diagnosis of CGD:

                       C. Absent or significantly reduced in expression or abnormal size of any of
                       the 5 phox components (gp91 phox, p47 phox, p22 phox, p67phox, and p40phox)
                       of NADPH oxidase, by either:

                         -  Western blot

                         -  Northern blot OR D. Mutation in a gene encoding one of the 5 phox
                            components (gp91 phox, p47 phox, p22 phox, p67 phox, and p40 phox) of
                            NADPH oxidase that is predictive of a decreased or absent oxidative
                            burst. (Nonsense, frameshift, or previously described missense mutation
                            associated with CGD).

                       Molecular Diagnosis is Desirable In addition, molecular diagnosis (gene
                       sequencing and expression analysis) of CGD is desirable and should be
                       performed when possible.

                    2. Further Characterization of Oxidase Level, Longitudinal Study, Prospective
                       Cohort Patients who are to undergo transplantation during the study period
                       must be further characterized as oxidase-null or oxidase positive by level
                       of oxidase production by either:

                         -  DHR assay stimulation Index: where SI ≤ 2.5 will be classified as
                            oxidase-null CGD. Those with SI &gt; 2.5 will be classified as oxidase
                            positive CGD. A single validated test that is accepted by the PID-CGD
                            Review Panel is adequate, but testing on two occasions for validation
                            is desirable. OR

                         -  Ferricytochrome C reduction assay of granulocytes with O2 &lt; 2.3 nmoles
                            /106 cells/h classified as oxidase-null CGD. A single validated test
                            that is accepted by the PID-CGD Review Panel is adequate, but testing
                            on two occasions for validation is desirable.

                       OR

                       o Genetic sequencing reporting a mutation that is unequivocally associated
                       to absent oxidase production. (e.g. null mutations) will be classified as
                       oxidase-null CGD (See discussion in Appendix I for how family history,
                       genotype and CGD mutation information will be applied to assigning patients
                       lacking any quantitative oxidase activity measurements to residual
                       oxidase-null or residual oxidase-positive groups).

                    3. Longitudinal Study, Retrospective Cohort Patients who have already been
                       transplanted will be included regardless of whether further characterization
                       by oxidase level (or genotype/mutation data) is possible or not.

               -  Non-Transplanted CGD Patients with Birth Year In or After 1988 A non-transplant
                  (conventional therapy) group of CGD subjects will be enrolled in the longitudinal
                  study. The non-transplant subjects will be selected from the potentially eligible
                  (retrospective) patient cohort with diagnosis of CGD treated with conventional
                  non-transplant therapy. Participating sites will enter their entire retrospective
                  cohort of CGD patients having birth year in or after 1988 into the registration
                  cohort for this protocol. Baseline for both non-transplant subjects and HCT
                  subjects for the purpose of comparing survival will be the year of birth.
                  However, for non-transplant subjects, many of the detailed analyses such as
                  infection and autoimmune complication rates will be assessed in the year
                  preceding the date of last contact.

          -  Participant Inclusion Criteria (Part 2 - Cross-Sectional Analysis) To participate in
             the Cross-Sectional Analysis, patients must have previously been enrolled into the
             Longitudinal Analysis of Protocol 6903. All transplanted subjects in the
             Cross-Sectional Analysis are surviving and shall have at least 3 years of follow-up
             post-transplant to be included. Non-transplanted CGD subjects will become eligible for
             consideration for the Cross-Sectional Analysis if they were eligible and enrolled in
             the retrospective cohort of the Longitudinal Analysis, and if/when they are &gt; 3 years
             post-diagnosis of CGD. Provision of written informed consent will be required for
             inclusion in the Cross-Sectional Analysis.

        Exclusion Criteria:

          -  Participant Exclusion Criteria (Longitudinal and Cross- Sectional Analyses)

               -  Presence of other primary immunodeficiency syndromes that do not meet the
                  clinical and laboratory criteria for CGD.

               -  Rac2 Deficiency

               -  Myeloperoxidase Deficiency (MPO Deficiency)

               -  Glutathione deficiency

               -  Leukocyte adhesion deficiency syndrome

          -  Non-transplant subjects:

               -  The above exclusions pertain.

               -  In addition, non-transplant subjects will be excluded if the only assessment of
                  oxidase function available is the nitroblue tetrazolium (NBT) test (a
                  non-quantitative test).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth M. Kang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harry L Malech, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredrick Goldman, MD</last_name>
      <phone>205-939-5855</phone>
      <email>fgoldman@peds.uab.edu</email>
    </contact>
    <investigator>
      <last_name>Fredrick Goldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly Miller, MD</last_name>
      <phone>602-933-0920</phone>
      <email>hmiller2@phoenixchildrens.com</email>
    </contact>
    <investigator>
      <last_name>Holly Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neena Kapoor, MD</last_name>
      <phone>323-361-2217</phone>
      <email>nkapoor@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Neena Kapoor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1752</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theodore Moore, MD</last_name>
      <phone>310-825-6708</phone>
      <email>tbmoore@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Theodore Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-1278</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Dunn, MA</last_name>
      <phone>415-502-0203</phone>
      <email>Elizabeth.Dunn@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Morton Cowan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital/ Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katja Weinacht, MD</last_name>
      <phone>617-919-8775</phone>
      <email>kgw1@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Katja Weinacht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger Giller, MD</last_name>
      <phone>720-777-8563</phone>
      <email>Roger.Giller@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Giller Roger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred I. duPont Hospital for Children/Nemours</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emi Caywood, MD</last_name>
      <phone>302-651-5500</phone>
      <email>Emi.caywood@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Emi Caywood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center, Washington DC</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blachy Saldaña, MD</last_name>
      <phone>202-476-4561</phone>
      <email>Bjdavilas1@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>Blachy Saldaña, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital, St. Petersburg FL</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Oshrine, MD</last_name>
      <phone>727-767-4176</phone>
      <email>Boshrin1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin Oshrine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta/ Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Stenger, MD</last_name>
      <phone>404-785-1272</phone>
      <email>Elizabeth.Stenger@choa.org</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Stenger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morris Kletzel, MD</last_name>
      <phone>773-880-4598</phone>
      <email>MKletzel16@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Morris Kletzel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of New Orleans at LSUHSC</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lolie Yu, MD</last_name>
      <phone>504-896-9740</phone>
      <email>lyu@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Lolie Yu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NIH Clinical Center Genetic Immunotherapy Section</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Kang, MD</last_name>
      <phone>301-402-7567</phone>
      <email>ekang@niaid.nih.gov</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Kang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-Yun Pai, MD</last_name>
      <phone>617-919-2508</phone>
      <email>sung-yun.pai@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Sung-Yun Pai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Vander Lugt, MD</last_name>
      <phone>737-936-9814</phone>
      <email>marvande@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Vander Lugt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angie Smith, MD</last_name>
      <phone>612-626-2778</phone>
      <email>smith719@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Angie Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Bram, MD</last_name>
      <phone>507-284-2695</phone>
      <email>Bramr@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Bram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Hospital/ St. Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Sanders, RN</last_name>
      <phone>314-268-2700</phone>
      <email>Wendy_Sanders@ssmhc.com</email>
    </contact>
    <investigator>
      <last_name>Alan Knutsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University/ St.Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shalini Shenoy, MD</last_name>
      <phone>314-454-6018</phone>
      <email>Shenoy@kids.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Shalini Shenoy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfred Gillio, MD</last_name>
      <phone>201-996-5645</phone>
      <email>AGillio@HackensackUMC.org</email>
    </contact>
    <investigator>
      <last_name>Alfred Gillio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Bhatia, MD</last_name>
      <phone>212-305-9138</phone>
      <email>mb2476@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Monica Bhatia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farid Boulad, MD</last_name>
      <phone>212-639-6684</phone>
      <email>bouladf@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Farid Boulad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center/ Golisano Children's Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Andolina, MD</last_name>
      <phone>585-276-3229</phone>
      <email>Jeffrey_andolina@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Andolina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Medical College, Maria Fareri Children's Hospital</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allyson Flower, MD</last_name>
      <phone>914-493-7997</phone>
      <email>Allyson_flower@nymc.edu</email>
    </contact>
    <investigator>
      <last_name>Allyson Flower, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suhag Parikh, MD</last_name>
      <phone>919-668-1121</phone>
      <email>suhag.parikh@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Suhag Parikh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Bleesing, MD</last_name>
      <phone>513-636-0992</phone>
      <email>Jack.Bleesing@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Jacob Bleesing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies/ University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jignesh Dalal, MD</last_name>
      <phone>216-844-3345</phone>
      <email>Jignesh.Dalal@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Jignesh Dalal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rolla Abu-Arja, MD</last_name>
      <phone>614-722-3582</phone>
      <email>Rolla.abu-arja@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Rolla Abu-Arja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evan Shereck, MD</last_name>
      <phone>503-494-0829</phone>
      <email>Shereck@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Evan Shereck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Heimall, MD</last_name>
      <phone>215-590-2549</phone>
      <email>heimallj@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Heimall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hey Chong, MD</last_name>
      <phone>412-692-5103</phone>
      <email>Hey.chong@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Hey Chong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewelina Mamcarz, MD</last_name>
      <phone>901-595-8343</phone>
      <email>ewelina.mamcarz@stjude.orgv</email>
    </contact>
    <investigator>
      <last_name>Ewelina Mamcarz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Aquino, MD</last_name>
      <phone>214-648-8800</phone>
      <email>victor.aquino@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Victor Aquino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hosp. CRS/Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chivon McMullenJackson, MD</last_name>
      <phone>832-824-1339</phone>
      <email>cdmcmull@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>William Shearer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Children's Hospital of South Texas/Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Troy Quigg, MD</last_name>
      <phone>210-575-7348</phone>
      <email>Troy.Quigg@MHShealth.com</email>
    </contact>
    <investigator>
      <last_name>Troy Quigg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center/ University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Shyr, MD</last_name>
      <phone>801-662-4736</phone>
      <email>David.Shyr@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>David Shyr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauri M Burroughs, MD</last_name>
      <phone>206-667-2396</phone>
      <email>lburroug@fhcrc.org</email>
    </contact>
    <investigator>
      <last_name>Lauri M Burroughs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin/ American Family Children's Hospital</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705-2275</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth DeSantes, MD</last_name>
      <phone>608-263-8563</phone>
      <email>kbdesantes@pediatrics.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth DeSantes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-4874</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica S Thakar, MD</last_name>
      <phone>414-266-6848</phone>
      <email>mthakar@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Monica S Thakar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicola Wright, MD</last_name>
      <phone>403-955-3035</phone>
      <email>Nicola.Wright@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Nicola Wright, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff Davis, MD</last_name>
      <phone>604-875-3577</phone>
      <email>jdavis@cw.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Jeff Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoff Cuvelier, MD</last_name>
      <phone>204-787-8689</phone>
      <email>geoff.cuvelier@cancercare.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Geoff Cuvelier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1XB</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eyal Grunebaum, MD</last_name>
      <phone>416-813-7654</phone>
      <email>Eyal.Grunebaum@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Eyal Grunebaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU St. Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elie Haddad, MD</last_name>
      <phone>514-345-4931</phone>
      <phone_ext>6217</phone_ext>
      <email>elie.haddad@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>Elie Haddad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>https://www.niaid.nih.gov</url>
    <description>The National Institute of Allergy and Infectious Diseases (NIAID)</description>
  </link>
  <link>
    <url>http://rarediseasesnetwork.epi.usf.edu/index.htm</url>
    <description>The Rare Diseases Clinical Research Network (RDCRN)</description>
  </link>
  <link>
    <url>http://rarediseasesnetwork.epi.usf.edu/PIDTC/</url>
    <description>Primary Immune Deficiency Treatment Consortium (PIDTC)</description>
  </link>
  <reference>
    <citation>Griffith LM, Cowan MJ, Kohn DB, Notarangelo LD, Puck JM, Schultz KR, Buckley RH, Eapen M, Kamani NR, O'Reilly RJ, Parkman R, Roifman CM, Sullivan KE, Filipovich AH, Fleisher TA, Shearer WT. Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs. J Allergy Clin Immunol. 2008 Dec;122(6):1087-96. doi: 10.1016/j.jaci.2008.09.045. Epub 2008 Nov 6.</citation>
    <PMID>18992926</PMID>
  </reference>
  <results_reference>
    <citation>Griffith LM, Cowan MJ, Notarangelo LD, Kohn DB, Puck JM, Pai SY, Ballard B, Bauer SC, Bleesing JJ, Boyle M, Brower A, Buckley RH, van der Burg M, Burroughs LM, Candotti F, Cant AJ, Chatila T, Cunningham-Rundles C, Dinauer MC, Dvorak CC, Filipovich AH, Fleisher TA, Bobby Gaspar H, Gungor T, Haddad E, Hovermale E, Huang F, Hurley A, Hurley M, Iyengar S, Kang EM, Logan BR, Long-Boyle JR, Malech HL, McGhee SA, Modell F, Modell V, Ochs HD, O'Reilly RJ, Parkman R, Rawlings DJ, Routes JM, Shearer WT, Small TN, Smith H, Sullivan KE, Szabolcs P, Thrasher A, Torgerson TR, Veys P, Weinberg K, Zuniga-Pflucker JC; workshop participants. Primary Immune Deficiency Treatment Consortium (PIDTC) report. J Allergy Clin Immunol. 2014 Feb;133(2):335-47. doi: 10.1016/j.jaci.2013.07.052. Epub 2013 Oct 15.</citation>
    <PMID>24139498</PMID>
  </results_reference>
  <results_reference>
    <citation>Griffith LM, Cowan MJ, Notarangelo LD, Kohn DB, Puck JM, Shearer WT, Burroughs LM, Torgerson TR, Decaluwe H, Haddad E; workshop participants. Primary Immune Deficiency Treatment Consortium (PIDTC) update. J Allergy Clin Immunol. 2016 Aug;138(2):375-85. doi: 10.1016/j.jaci.2016.01.051. Epub 2016 Apr 22. Review.</citation>
    <PMID>27262745</PMID>
  </results_reference>
  <results_reference>
    <citation>Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, Kapoor N, Hanson IC, Filipovich AH, Jyonouchi S, Sullivan KE, Small TN, Burroughs L, Skoda-Smith S, Haight AE, Grizzle A, Pulsipher MA, Chan KW, Fuleihan RL, Haddad E, Loechelt B, Aquino VM, Gillio A, Davis J, Knutsen A, Smith AR, Moore TB, Schroeder ML, Goldman FD, Connelly JA, Porteus MH, Xiang Q, Shearer WT, Fleisher TA, Kohn DB, Puck JM, Notarangelo LD, Cowan MJ, O'Reilly RJ. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med. 2014 Jul 31;371(5):434-46. doi: 10.1056/NEJMoa1401177.</citation>
    <PMID>25075835</PMID>
  </results_reference>
  <results_reference>
    <citation>Haddad E, Allakhverdi Z, Griffith LM, Cowan MJ, Notarangelo LD. Survey on retransplantation criteria for patients with severe combined immunodeficiency. J Allergy Clin Immunol. 2014 Feb;133(2):597-9. doi: 10.1016/j.jaci.2013.10.022. Epub 2013 Dec 10.</citation>
    <PMID>24331379</PMID>
  </results_reference>
  <results_reference>
    <citation>Shearer WT, Dunn E, Notarangelo LD, Dvorak CC, Puck JM, Logan BR, Griffith LM, Kohn DB, O'Reilly RJ, Fleisher TA, Pai SY, Martinez CA, Buckley RH, Cowan MJ. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol. 2014 Apr;133(4):1092-8. doi: 10.1016/j.jaci.2013.09.044. Epub 2013 Nov 28.</citation>
    <PMID>24290292</PMID>
  </results_reference>
  <results_reference>
    <citation>Dvorak CC, Cowan MJ, Logan BR, Notarangelo LD, Griffith LM, Puck JM, Kohn DB, Shearer WT, O'Reilly RJ, Fleisher TA, Pai SY, Hanson IC, Pulsipher MA, Fuleihan R, Filipovich A, Goldman F, Kapoor N, Small T, Smith A, Chan KW, Cuvelier G, Heimall J, Knutsen A, Loechelt B, Moore T, Buckley RH. The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the primary immune deficiency treatment consortium prospective study 6901. J Clin Immunol. 2013 Oct;33(7):1156-64. doi: 10.1007/s10875-013-9917-y. Epub 2013 Jul 2.</citation>
    <PMID>23818196</PMID>
  </results_reference>
  <results_reference>
    <citation>Griffith LM, Cowan MJ, Notarangelo LD, Puck JM, Buckley RH, Candotti F, Conley ME, Fleisher TA, Gaspar HB, Kohn DB, Ochs HD, O'Reilly RJ, Rizzo JD, Roifman CM, Small TN, Shearer WT; Workshop Participants. Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management. J Allergy Clin Immunol. 2009 Dec;124(6):1152-60.e12. doi: 10.1016/j.jaci.2009.10.022.</citation>
    <PMID>20004776</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2014</study_first_submitted>
  <study_first_submitted_qc>March 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2014</study_first_posted>
  <last_update_submitted>October 13, 2017</last_update_submitted>
  <last_update_submitted_qc>October 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Granulomatous Disease, Chronic</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation (HSCT)</keyword>
  <keyword>bone marrow transplant (BMT)</keyword>
  <keyword>non-transplant</keyword>
  <keyword>factors associated with best outcomes of transplant in CGD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Granuloma</mesh_term>
    <mesh_term>Granulomatous Disease, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

